Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells

Table 2 The effect of BH3 mimetic combinations on annexin V/propidium iodide staining

	Annexin V/PI positive cells (% of total)
	OVCAR-8	OVCAR-3	IGROV-1	COV-362	OVCAR-4	OVSAHO
Control	3 ± 1	4 ± 2	5 ± 1	2 ± 1	5 ± 2	2 ± 1
Carboplatin	11 ± 2	10 ± 3	15 ± 5	3 ± 1	75 ± 9	3 ± 2
ABT-737	6 ± 2	8 ± 1	5 ± 1	2 ± 1	17 ± 11	5 ± 1
ABT-199	4 ± 2	4 ± 1	5 ± 2	2 ± 1	8 ± 6	2 ± 1
WEHI-539	5 ± 2	6 ± 2	12 ± 5	2 ± 1	13 ± 9	6 ± 1
CbPt + ABT-737	72 ± 3**	58 ± 4*	39 ± 7	17 ± 5**	88 ± 4	4 ± 1
CbPt + ABT-199	13 ± 1	12 ± 7	16 ± 4	4 ± 1	84 ± 3	2 ± 1
CbPt + WEHI-539	79 ± 2**	71 ± 10*	35 ± 6	14 ± 2**	88 ± 5	5 ± 2

The indicated cells were exposed to 66 μM carboplatin or the indicated BH3 mimetic for 48 h, the cells were labelled with annexin V and propidium iodide and assessed by flow cytometery. The percentage of cells that stained positive with both annexin V and propidium iodide is shown. This was significantly different where shown paired t-test, *, P < 0.05; **, P < 0.01) from the percentage of annexinV/propidium iodide positive cells expected from the activity of the single agents and calculated from the Bliss independence criterion

ISSN: 1757-2215